The Canadian Drug Expert Committee (CDEC) has recommended that alirocumab be reimbursed as an adjunct to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia who require additional lowering of low density lipoprotein cholesterol (LDL-C), if certain clinical criteria and conditions are met.

The CDEC has also recommended that alirocumab be reimbursed as an adjunct to diet and maximally tolerated statin therapy in adult patients at high risk for cardiovascular events, who require additional lowering of LDL-C, if certain clinical criteria and conditions are met.

One of the conditions is a reduced price.

Read CDEC recommendation